Check out this morning's top movers from around Wall Street, compiled by The Fly. 

HIGHER -

• Affimed N.V. (AFMD) up 35% after announcing initial clinical data from an investigator-sponsored study at The University of Texas MD Anderson Cancer Center evaluating cord blood-derived natural killer cells pre-complexed with Affimed's innate cell engager AFM13
• Greenwich LifeSciences (GLSI) up 25% after announcing the abstract results of the final five-year immune response data of the Phase IIb clinical trial at the 2021 AACR annual meeting
• Celcuity (CELC) up 67% after reporting preliminary data for the 103 patients enrolled in the expansion portion of an ongoing Phase 1b clinical trial evaluating gedatolisib, a PI3K/mTOR inhibitor, plus Ibrance and endocrine therapy, in ER+/HER2- advanced or metastatic breast cancer patients
• FuboTV (FUBO) up 8% after announcing it has acquired the exclusive live streaming rights to the Qatar World Cup 2022 Qualifying matches of South American Football Confederation
• Sunworks (SUNW) up 3% after the company and Solcius announced that they have entered into a definitive agreement pursuant to which a subsidiary of Sunworks will acquire Solcius, valued at $51.8M on a cash-free and debt-free basis, in an all-cash transaction

DOWN AFTER EARNINGS - 

• JinkoSolar (JKS) down 9% 

LOWER - 

• TSMC (TSM) down 1% after reporting its March revenue was up 13.7% y/y to NT$129.13B
• ChipMOS (IMOS) down 1% after reporting Q1 and March revenue figures
• Global Ship Lease (GSL) down 6% after 4.5M share spot secondary offering priced at $12.50
• Provention Bio (PRVB) down 32% after receiving a notification from the FDA stating that, as part of its ongoing review of the company's Biologic License Application for teplizumab for the delay or prevention of clinical type 1 diabetes, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time